Vernalis drug discovery deal with Genentech
Cambridge UK drug discovery expertise continues to be in hot demand with the global ‘greats’ of biotech and Pharma.
Genentech – considered the founder of the biotechnology industry worldwide – has sought out Vernalis plc for a major collaboration.
Now a member of the Roche Group, Genentech, will utilise Vernalis' fragment and structure-based drug discovery platform against an undisclosed target.
The financial terms of the alliance are not being disclosed.
Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture and commercialise medicines to treat patients with serious or life-threatening medical conditions.
It remains among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.
As part of a merger Roche and Genentech combined their pharmaceutical operations in the US. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the States.
Ian Garland, CEO of Vernalis, said: “We are delighted that Genentech has selected Vernalis to work with it on this target. Its selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations.
“We look forward to building a close working relationship with Genentech and ultimately a successful collaboration.”
• PHOTOGRAPH SHOWS: Ian Garland